Immunosuppressant

Patients with systemic lupus erythematosus who are positive for anti-Ro60 or anti-Ro52 antibodies may face higher disease activity and more intensive treatment needs, according to data published in Rheumatology.

Mycophenolic acid, sirolimus and steroids were associated with an increased risk for COVID-19-related hospitalization among those who underwent kidney, liver, heart or lung transplant, data from JAMA Network Open showed.

Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed no certain impact on kidney function.

NAPLES, Florida — Jennifer L. Seminerio, MD, spoke with Healio about key takeaways from her 2022 ACG/FGS Spring Symposium presentation, which focused on treatment for mild to moderate ulcerative colitis and Crohn’s disease.

With a risk for COVID-19 similar to the general population, patients with inflammatory bowel disease should be receiving the “same exact treatment” as they did prior to the pandemic, according to a presenter at the GUILD Conference.

The American College of Rheumatology has updated its COVID-19 vaccine clinical guidance for patients with rheumatic diseases to recommend a fourth mRNA vaccine dose in patients receiving immunosuppressive or immunomodulatory therapy.

Children with inflammatory bowel disease had a low risk of severe COVID-19 infection, even while taking immunosuppressants, according to a poster.

One-third of patients with systemic lupus erythematosus demonstrate low response to the COVID-19 vaccine, a “blunted effect” linked to use of any immunosuppressive agent except antimalarials, according to a presenter at ACR Convergence 2021.

Among pediatric patients with Crohn’s disease and ulcerative colitis, the risk for incidence of intestinal resection and colectomy after 5 years of diagnosis decreased over a 24-year period, according to a presenter at UEG Week.